• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Patients With Newly Diagnosed, High-Risk Myeloma See High MRD Negative Rates With Isa-KRd

by | Oct 1, 2023 | Uncategorized

Source: CureToday articles Treatment with the combination of Sarclisa, Kyprolis, Revlimid and Isa-KRd generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status. Read...

Mezigdomide Regimen Promising for Relapsed/Refractory Myeloma

by | Sep 29, 2023 | Uncategorized

Source: CureToday articles Mezigdomide plus Velcade and dexamethasone or Kyprolis and dexamethasone showed promising response rates across multiple doses in patients with relapsed or refractory multiple myeloma, research showed. Read More

Health care professionals express support for postpartum depression, myeloma treatments

by | Sep 28, 2023 | Uncategorized

Analysis of online conversations among health care professionals on social media during August revealed significant support for the first oral treatment for postpartum depression.The agency approved zuranolone (Zurzuvae, Sage Therapeutics) on Aug. 7.The analysis also...

Aphexda Plus Filgrastim Boosts Stem Cell Mobilization in Patients With Myeloma

by | Sep 27, 2023 | Uncategorized

Source: CureToday articles The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma. Read More

Blenrep Improves Durability in Relapsed/Refractory Multiple Myeloma

by | Sep 14, 2023 | Uncategorized

Source: CureToday articles Blenrep improves durability and provides meaningful response rates to patients with relapsed/refractory multiple myeloma, researchers found. Read More

FDA approves Aphexda for mobilization of stem cells before transplant in multiple myeloma

by | Sep 11, 2023 | Uncategorized

The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into peripheral blood during collection for subsequent autologous transplantation in individuals with multiple myeloma.Motixafortide (Aphexda, BioLineRx) —...
« Older Entries
Next Entries »

Recent Content

  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
  • Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
  • A Year of Resilience: Looking Back After a Myeloma Diagnosis
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT